|
Description When paclitaxel first came into the market, American Food and Drug Administration (FDA) only approved it to be used in the clinical treatment of advanced non-small cell cancer and advanced ovarian cancer. As paclitaxel rapidly becomes popular in the clinic over the next 20 years, at present it is utilized in the treatment of advanced breast carcinoma, prostatic cancer, Kaposi’s sarcoma, head and neck cancer, cutaneous carcinoma and some other common malignant tumors. Ever since it came into the market in 1992, paclitaxel, the best-selling phytogenic anticarcinogen, has brought in an accumulated sales value of over USD 20 billion. Before 2000, 90% of the global paclitaxel market was dominated by Bristol-Myers Squibb Company. After the patent of paclitaxel expired, over 100 companies around the world are engaged in the production of the APIs and preparations of paclitaxel.
China is one of the leading countries with diagnoses of cancer. In China 5 million to 6 million new cases of cancer are identified each year. However, the overwhelmingly high price of paclitaxel injection (CNY 1600 for one dose of paclitaxel injection in the past) has constrained its sale in the Chinese market. Therefore, the sale of paclitaxel in China has been poor in the past ten years. However, ever since Jiangsu Heng Rui Medicine Co., Ltd started to produce the APIs and preparations of Docetaxel, the situation of China lagging behind developed countries in the consumption of paclitaxel has changed. Since domestic paclitaxel injection is much cheaper than its imported counterpart, the formerly high-end medicine has truly become affordable to ordinary people. At present the market price for each dose of domestic paclitaxel injection (30mg/5ml) ranges from CNY 285 to CNY 550. Annual sales value of paclitaxel in China has risen from less than CNY 400 million in 2005 to CNY 1,388 million in 2014, and its CAGR during the period of 2005-2014 was 17.3%. According to the market survey of CRI, leading enterprises in China paclitaxel market include Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd, The Department of Cancer, Bristol-Myers Squibb Company (U.S.), American Pharmaceutical Partners and Abraxis BioScience (U.S.), among which Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd took up over half of the market share in 2014
As planted forests of Chinese yew increases, the output of paclitaxel in China is expected to keep growing.
It is estimated that the market size of paclitaxel in China will keep growing in the next few years. Readers can have access to at least the following information through reading this report: -market size of paclitaxel in China
-competitive landscape of paclitaxel in Chinese market
-price of paclitaxel produced by different enterprises in China
-market outlook of paclitaxel in China The author suggests the following groups of people purchase this report: -manufacturers of antineoplastic drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service
|
현재위치 : 
